Two Surveys Raise Questions about Willingness of Consumers to Pay Pathology Laboratories for Expensive Genetic Cancer Tests

This finding is reinforced by the fact that high-deductible health plans are now the second most popular plan option offered by the nation’s employers Getting paid for expensive genetic cancer tests is likely to be tougher for clinical laboratories when the patient is covered by a high-deductible health plan. There are two trends that are contributing to this situation, each highlighted by recently-published studies. One trend is the rapid growth of consumer-driven health plans (CDHPs). The...

Proactive Healthcare Emphasized as United Kingdom Works to Reform Healthcare System and Clinical Pathology Laboratory Testing

Speakers at Frontiers in Laboratory Medicine See Increased Role for Pathology DATELINE: BIRMINGHAM, ENGLAND—As our North American readers of Dark Daily arrive for work this morning, it will be late afternoon here in the United Kingdom and the last presentations on the second day of the 10th annual Frontiers in Laboratory Medicine (FiLM) will be wrapping up. It was a packed auditorium this year at FiLM, as clinical biochemists, pathologists, and medical laboratory scientists gathered to learn...

Pathologists and Clinical Labs Can Expect to See More Companion Diagnostic Tests

Pharmaceutical Companies Partnering with IVD Manufacturers to Develop Companion Diagnostic Tests for their Therapeutic Drugs Growing acceptance of companion diagnostics is a trend with the potential to greatly increase the value that clinical pathology laboratory testing delivers to physicians, patients, and payers. In 2010, it was increasingly common to see a pharmaceutical company announce an agreement with an in vitro diagnostics (IVD) manufacturer to develop a companion diagnostic test...